دورية أكاديمية
أعرض في EDS

Enhanced Immune Responses and Protective Immunity to Zika Virus Induced by a DNA Vaccine Encoding a Chimeric NS1 Fused With Type 1 Herpes Virus gD Protein.

التفاصيل البيبلوغرافية
العنوان: Enhanced Immune Responses and Protective Immunity to Zika Virus Induced by a DNA Vaccine Encoding a Chimeric NS1 Fused With Type 1 Herpes Virus gD Protein.
المؤلفون: Pereira LR; Laboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Alves RPDS; Laboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Sales NS; Laboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Andreata-Santos R; Laboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Venceslau-Carvalho AA; Laboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Pereira SS; Laboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Castro-Amarante MF; Laboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Rodrigues-Jesus MJ; Laboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Favaro MTP; Laboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Chura-Chambi RM; Biotechnology Center, Institute of Energy and Nuclear Research (IPEN), São Paulo, Brazil., Morganti L; Biotechnology Center, Institute of Energy and Nuclear Research (IPEN), São Paulo, Brazil., Ferreira LCS; Laboratory of Vaccine Development, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
المصدر: Frontiers in medical technology [Front Med Technol] 2020 Dec 03; Vol. 2, pp. 604160. Date of Electronic Publication: 2020 Dec 03 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Country of Publication: Switzerland NLM ID: 101772626 Publication Model: eCollection Cited Medium: Internet ISSN: 2673-3129 (Electronic) Linking ISSN: 26733129 NLM ISO Abbreviation: Front Med Technol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne, Switzerland : Frontiers, [2019]-
مستخلص: Zika virus (ZIKV) is a globally-distributed flavivirus transmitted to humans by Aedes mosquitoes, usually causing mild symptoms that may evolve to severe conditions, including neurological alterations, such as neonatal microcephaly and Guillain-Barré syndrome. Due to the absence of specific and effective preventive methods, we designed a new subunit vaccine based on a DNA vector (pgDNS1-ZIKV) encoding the non-structural protein 1 (NS1) genetically fused to the Herpes Simplex Virus (HSV) glycoprotein D (gD) protein. Recombinant plasmids were replicated in Escherichia coli and the expression of the target protein was confirmed in transfected HEK293 cells. C57BL/6 and AB6 (IFNAR1-/-) mice were i.m. immunized by electroporation in order to evaluate pgDNS1-ZIKV immunogenicity. After two doses, high NS1-specific IgG antibody titers were measured in serum samples collected from pgDNS1-ZIKV-immunized mice. The NS1-specific antibodies were capable to bind the native protein expressed in infected mammalian cells. Immunization with pgDNS1-ZIKV increased both humoral and cellular immune responses regarding mice immunized with a ZIKV NS1 encoding vaccine. Immunization with pgDNS1-ZIKV reduced viremia and morbidity scores leading to enhanced survival of immunodeficient AB6 mice challenged with a lethal virus load. These results give support to the use of ZIKV NS1 as a target antigen and further demonstrate the relevant adjuvant effects of HSV-1 gD.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2020 Pereira, Alves, Sales, Andreata-Santos, Venceslau-Carvalho, Pereira, Castro-Amarante, Rodrigues-Jesus, Favaro, Chura-Chambi, Morganti and Ferreira.)
References: Nat Commun. 2020 Oct 19;11(1):5278. (PMID: 33077712)
PLoS Negl Trop Dis. 2014 Jan 09;8(1):e2636. (PMID: 24421913)
Nat Immunol. 2016 Sep;17(9):1102-8. (PMID: 27339099)
PLoS Pathog. 2018 Sep 13;14(9):e1007237. (PMID: 30212537)
MMWR Morb Mortal Wkly Rep. 2016 Jan 29;65(3):55-8. (PMID: 26820163)
BMC Biotechnol. 2018 Dec 12;18(1):78. (PMID: 30541520)
Clin Vaccine Immunol. 2016 Jun 06;23(6):460-469. (PMID: 27030586)
Viruses. 2020 May 06;12(5):. (PMID: 32384822)
Curr Opin Immunol. 2018 Aug;53:130-136. (PMID: 29753210)
J Immunol. 2009 Aug 1;183(3):1797-803. (PMID: 19592650)
PLoS One. 2018 Feb 6;13(2):e0192123. (PMID: 29408873)
Front Immunol. 2020 Mar 25;11:517. (PMID: 32269575)
Arch Virol. 2016 Mar;161(3):665-8. (PMID: 26611910)
Nat Biotechnol. 2006 Jul;24(7):817-9. (PMID: 16767078)
Adv Exp Med Biol. 2018;1062:215-239. (PMID: 29845536)
Open Forum Infect Dis. 2017 May 18;4(2):ofx103. (PMID: 28702470)
Cell. 2017 Mar 9;168(6):1114-1125.e10. (PMID: 28222903)
Sci Adv. 2018 Jul 04;4(7):eaar4297. (PMID: 29978039)
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W509-12. (PMID: 18463140)
Mol Pharm. 2011 Dec 5;8(6):2320-30. (PMID: 21985578)
J Infect Dis. 2010 Jul 15;202(2):223-33. (PMID: 20536361)
mBio. 2019 Apr 2;10(2):. (PMID: 30940710)
Front Immunol. 2019 Jun 11;10:1316. (PMID: 31244855)
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6244-9. (PMID: 19332782)
J Virol. 2018 Mar 14;92(7):. (PMID: 29343577)
Cell Host Microbe. 2016 May 11;19(5):720-30. (PMID: 27066744)
Antiviral Res. 2013 May;98(2):192-208. (PMID: 23523765)
PLoS Pathog. 2017 Aug 3;13(8):e1006487. (PMID: 28771605)
Nat Commun. 2018 Nov 1;9(1):4560. (PMID: 30385750)
Vaccine. 2017 Dec 19;35(52):7240-7249. (PMID: 29174677)
N Engl J Med. 2016 Sep 22;375(12):1202-4. (PMID: 27653589)
Nat Commun. 2018 Aug 2;9(1):3042. (PMID: 30072692)
Nature. 2016 Aug 25;536(7617):474-8. (PMID: 27355570)
Cell Host Microbe. 2017 Jan 11;21(1):35-46. (PMID: 28081442)
Nat Commun. 2018 Aug 3;9(1):3067. (PMID: 30076287)
Sci Rep. 2017 Nov 7;7(1):14769. (PMID: 29116169)
Emerg Infect Dis. 2009 Sep;15(9):1347-50. (PMID: 19788800)
NPJ Vaccines. 2020 Sep 15;5:86. (PMID: 33014434)
J Infect Dis. 1998 Jul;178(1):92-100. (PMID: 9652427)
Front Immunol. 2020 Jun 18;11:1252. (PMID: 32655561)
Nat Med. 2008 Feb;14(2):205-12. (PMID: 18193057)
Microbes Infect. 2005 Dec;7(15):1541-50. (PMID: 16213178)
J Virol. 2017 Oct 27;91(22):. (PMID: 28835502)
Viruses. 2018 Oct 31;10(11):. (PMID: 30384472)
N Engl J Med. 2016 Jun 2;374(22):2142-51. (PMID: 27028667)
Open Forum Infect Dis. 2018 Dec 19;6(1):ofy352. (PMID: 30697574)
Mol Cancer Ther. 2017 Sep;16(9):1922-1933. (PMID: 28522585)
Nat Commun. 2018 Aug 7;9(1):3136. (PMID: 30087337)
Infect Genet Evol. 2020 Nov;85:104521. (PMID: 32882433)
J Immunol. 2002 Jul 15;169(2):657-64. (PMID: 12097367)
Virus Res. 2014 Mar 6;181:53-60. (PMID: 24434336)
Immunity. 2005 Jul;23(1):41-51. (PMID: 16039578)
Nature. 2016 May 11;534(7606):267-71. (PMID: 27279226)
Nature. 2017 Mar 9;543(7644):248-251. (PMID: 28151488)
Science. 2016 Sep 9;353(6304):1129-32. (PMID: 27492477)
FEMS Immunol Med Microbiol. 2003 Jan 21;35(1):25-31. (PMID: 12589954)
NPJ Vaccines. 2018 Jul 24;3:29. (PMID: 30062066)
Cell Rep. 2020 Apr 28;31(4):107566. (PMID: 32348763)
Sci Rep. 2017 Aug 30;7(1):10047. (PMID: 28855646)
Vaccines (Basel). 2020 Aug 31;8(3):. (PMID: 32878023)
Nat Rev Microbiol. 2011 May;9(5):369-81. (PMID: 21478902)
Hum Gene Ther. 2009 Nov;20(11):1269-78. (PMID: 19619001)
Rev Med Virol. 2007 May-Jun;17(3):205-15. (PMID: 17295428)
Science. 2016 Aug 19;353(6301):823-6. (PMID: 27417494)
Annu Rev Immunol. 2010;28:389-411. (PMID: 20307212)
Science. 2016 Oct 14;354(6309):237-240. (PMID: 27708058)
Sci Transl Med. 2017 Dec 13;9(420):. (PMID: 29237759)
Front Immunol. 2019 Jul 18;10:1651. (PMID: 31379848)
Sci Adv. 2019 Dec 11;5(12):eaax2388. (PMID: 31844662)
Immunol Rev. 2011 Nov;244(1):169-87. (PMID: 22017438)
Mayo Clin Proc. 2019 Dec;94(12):2572-2586. (PMID: 31806107)
Science. 2020 Aug 28;369(6507):1123-1128. (PMID: 32855339)
Hum Gene Ther. 2013 Oct;24(10):861-70. (PMID: 24007495)
Cell Host Microbe. 2010 Feb 18;7(2):128-39. (PMID: 20153282)
PLoS Negl Trop Dis. 2013 Jul 18;7(7):e2330. (PMID: 23875054)
Cell. 2016 May 19;165(5):1081-1091. (PMID: 27180225)
فهرسة مساهمة: Keywords: DNA vaccine; HSV-1; NS1 protein; Zika virus; flavivirus; gD protein
تواريخ الأحداث: Date Created: 20220120 Latest Revision: 20221229
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8757838
DOI: 10.3389/fmedt.2020.604160
PMID: 35047887
قاعدة البيانات: MEDLINE
الوصف
تدمد:2673-3129
DOI:10.3389/fmedt.2020.604160